Oncology

Clear out clearnance rubbish scrap heap
Biotech

Bayer bails on Vividion tumor drug in early-stage clear-out

Bayer has cleared out four cancer candidates from its early-stage pipeline, including a STAT3 inhibitor acquired as part of its buyout of Vividion.
James Waldron Nov 12, 2025 8:10am
pipeline pipes RD research

Cullinan puts kibosh on 2 cancer assets amid autoimmune refocus

Nov 6, 2025 1:26pm
Novo Nordisk

Novo drops oncology ambitions, early-stage MASH prospects

Nov 5, 2025 7:21am
GSK ESMO

GSK loses hope for CD226 cancer therapies, dropping ph. 2 assets

Oct 29, 2025 6:29am
graphic of a larger shark chomping up a smaller one

Cardiometabolic field drives M&A while cancer deals drop: report

Oct 27, 2025 2:39pm
Illustration connected puzzle pieces with the acronym MA

Ipsen inks €1B buyout of French biotech ImCheck

Oct 22, 2025 10:33am
More News

Boehringer digs in on ADCs with $991M AimedBio licensing accord

Oct 15, 2025 10:05am

Tubulis touts $361M series C as next-gen ADC data drop nears

Oct 15, 2025 5:01am

Turbine looks to turbocharge AstraZeneca's ADC discovery

Oct 9, 2025 6:00am

3 scientists win Nobel Prize for discovery of regulatory T cells

Oct 6, 2025 7:03am